Treatment of @entity1 with XXXX using stellate @entity616 .

@entity1 @entity2682 @entity726 @entity2644 @entity3971 @entity1341 @entity158 @entity1338 @entity3856 @entity551 @entity285 @entity616
BACKGROUND AND OBJECTIVES: management of @entity158 in @entity3856 is still a challenge. Corticosteroids and @entity551 agents, as well as evisceration and enucleation, are some of the strategies employed so far that are not always effective and, depending on the strategy, cause a deep emotional shock to the @entity1 . Given these issues, the aim of this case report is to demonstrate a new and viable option for the management of such @entity158 by treating the @entity3856 with the stellate @entity616 technique, a procedure that has never been described in the literature for this purpose. CASE REPORT: six @entity1 with @entity3856 , all caused by @entity726 , were treated; in these @entity1 , VAS (visual analogue scale for @entity158 assessment, in which 0 is the absence of @entity158 and 10 is the worst @entity158 ever experienced) ranged from 7 to 10. We opted for weekly sessions of stellate @entity616 with 4mL of @entity1341 (0.5%) without vasoconstrictor and @entity1338 1mcg/kg. Four @entity1 had excellent results at VAS, ranging between 0 and 3, and two remained asymptomatic (VAS=0), without the need for additional medication. The other two used @entity2682 300mg every 12h. CONCLUSION: currently, there are several therapeutic options for the treatment of @entity3856 , among which stand out the retrobulbar blocks with @entity2644 , @entity285 and @entity3971 . However, an effective strategy with low rate of serious complications, which is non-mutilating and improves the quality of life of the @entity1 , is essential. Then, stellate @entity616 arises as a demonstrably viable and promising option to meet this demand.
